Recursion Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

Delivered first clinical validation of the Recursion full stack AI Operating System in FAP, demonstrating translation from AI-driven biological ...
Hosted on MSN

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Q2 2025 Earnings Call Transcript

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Q2 2025 Earnings Call Transcript August 5, 2025 Recursion Pharmaceuticals, Inc. misses on earnings expectations. Reported EPS is $-0.41187 EPS, ...
Yahoo Finance

RECURSION PHARMACEUTICALS INC (RXRX.MX) Q3 FY2025 earnings call transcript

Earnings call Recursion ended Q3 2025 with $785M in cash and no financing needs through 2027, aided by a 35% expense reduction and $40M in partnership inflows YTD. A $30M milestone from Roche ...
Seeking Alpha

Recursion Pharmaceuticals, Inc. (RXRX) Q4 2024 Earnings Call Transcript

Welcome everybody to Recursion's Earnings Call. I'm Chris Gibson, Co-Founder and CEO, and I'm excited to take you through Recursions 2024, 2025 and the time ahead. So with that we'll jump into the ...
The Globe and Mail

Recursion Pharmaceuticals’ Earnings Call Highlights Growth and Challenges

Recursion Pharmaceuticals, Inc. recently held its earnings call, which conveyed an optimistic sentiment. The company is experiencing strong leadership transitions, maintaining a robust financial ...
Yahoo Finance

Recursion to Report Third Quarter 2025 Business Updates and Financial Results on November 5th

Salt Lake City, UT, Oct. 28, 2025 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX), a leading clinical stage TechBio company decoding biology to radically improve lives, announced today it will provide ...